OpenLB
Open Library of Bioscience
Advanced Search
Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia
May, 2019;32 Suppl 1 45-54.

Fosfomycin in infections caused by multidrug-resistant Gram-negative pathogens.

J Ruiz Ramos, M Salavert Lletí
Author Information
  1. M Salavert Lletí: Miguel Salavert Lletí. Unidad de Enfermedades Infecciosas. Hospital Universitario y Politécnico La Fe, Valencia. Av. Fernando Abril Martorell, nº 106; Valencia 46026. Spain. Salavert_mig@gva.es.
PMID: 31131592

Abstract

The alarming increase in antibiotic resistance rates reported for various pathogens has resulted in the use of alternative treatment policies. Given the fairly limited availability of new antimicrobial drugs, the reassessment of older antibiotics is now an interesting option. Fosfomycin, a bactericidal analog of phosphoenolpyruvate that has been previously been employed as an oral treatment for uncomplicated urinary tract infection, has recently raised interest among physicians worldwide. In general, the advanced resistance described in Gram-negative bacteria suggests that fosfomycin can be an appropriate treatment option for patients with highly resistant microbial infections. This review, which refers to key available data, focuses on the possibility of extending the use of fosfomycin beyond urinary tract infections and against multidrug-resistant Gram-negative bacteria.

References

  1. Lancet Infect Dis. 2017 Jul;17(7):726-734 [PMID: 28442293]
  2. Clin Microbiol Infect. 2015 Mar;21(3):254.e1-8 [PMID: 25618436]
  3. Antimicrob Agents Chemother. 2012 Nov;56(11):5744-8 [PMID: 22926565]
  4. Zentralbl Bakteriol. 1993 Aug;279(3):387-93 [PMID: 8219509]
  5. Chest. 2017 Jun;151(6):1239-1246 [PMID: 27890714]
  6. J Infect Chemother. 2016 May;22(5):273-80 [PMID: 26923259]
  7. Tohoku J Exp Med. 2014;233(4):301-5 [PMID: 25142281]
  8. Int J Antimicrob Agents. 2012 Mar;39(3):271-2 [PMID: 22236455]
  9. Antimicrob Agents Chemother. 2013 Mar;57(3):1421-7 [PMID: 23295934]
  10. Antimicrob Agents Chemother. 2014 Sep;58(9):5598-601 [PMID: 24982065]
  11. Expert Rev Anti Infect Ther. 2017 Dec;15(12):1123-1140 [PMID: 29172792]
  12. Clin Microbiol Rev. 2018 Feb 14;31(2): [PMID: 29444952]
  13. Rev Esp Quimioter. 2013 Mar;26(1):43-6 [PMID: 23546462]
  14. Eur Urol. 2001 Nov;40(5):576-88 [PMID: 11752870]
  15. J Lab Physicians. 2011 Jan;3(1):37-42 [PMID: 21701662]
  16. Eur J Clin Microbiol Infect Dis. 1997 Aug;16(8):575-80 [PMID: 9323468]
  17. Clin Infect Dis. 2010 Mar 1;50(5):625-63 [PMID: 20175247]
  18. Curr Clin Pharmacol. 2014 Feb;9(1):27-38 [PMID: 23489027]
  19. BMC Microbiol. 2015 Sep 03;15:177 [PMID: 26335352]
  20. Scand J Infect Dis. 2012 Mar;44(3):182-9 [PMID: 22176655]
  21. Clin Infect Dis. 2014 Oct 15;59(8):1105-12 [PMID: 25048851]
  22. J Neurosci Rural Pract. 2017 Jul-Sep;8(3):335-341 [PMID: 28694609]
  23. Pathol Biol (Paris). 1983 Jun;31(6):522-4 [PMID: 6348661]
  24. Antimicrob Agents Chemother. 2016 Aug 22;60(9):5623-4 [PMID: 27401568]
  25. Enferm Infecc Microbiol Clin. 2015 Dec;33(10):679.e1-679.e21 [PMID: 25976754]
  26. Clin Microbiol Infect. 2018 Oct;24(10):1070-1076 [PMID: 29410094]
  27. Clin Microbiol Rev. 2016 Apr;29(2):321-47 [PMID: 26960938]
  28. Jpn J Antibiot. 2000 Jul;53(7):522-31 [PMID: 11019386]
  29. Int J Antimicrob Agents. 2015 Jan;45(1):66-70 [PMID: 25450805]
  30. Drugs Context. 2018 May 29;7:212527 [PMID: 29872449]
  31. Antibiotics (Basel). 2017 Oct 31;6(4): [PMID: 29088073]
  32. Clin Infect Dis. 2008 Apr 1;46(7):1069-77 [PMID: 18444827]
  33. Int J Antimicrob Agents. 2009 Aug;34(2):111-20 [PMID: 19403273]
  34. Int J Antimicrob Agents. 2015 Nov;46(5):586-9 [PMID: 26391378]
  35. Pathog Dis. 2013 Feb;67(1):39-45 [PMID: 23620118]
  36. Clin Infect Dis. 2011 Mar 1;52(5):e103-20 [PMID: 21292654]
  37. Chemotherapy. 2017;62(2):100-104 [PMID: 27788499]
  38. Crit Care Med. 2013 Feb;41(2):580-637 [PMID: 23353941]
  39. Transplant Rev (Orlando). 2018 Jan;32(1):36-57 [PMID: 28811074]
  40. Rev Esp Quimioter. 2003 Mar;16(1):15-40 [PMID: 12750755]
  41. Future Microbiol. 2010 Jun;5(6):961-70 [PMID: 20521939]
  42. J Antimicrob Chemother. 2009 Sep;64(3):563-6 [PMID: 19561148]
  43. Curr Opin Infect Dis. 2018 Dec;31(6):499-505 [PMID: 30299353]
  44. Chemotherapy. 1977;23 Suppl 1:392-8 [PMID: 832540]
  45. J Cyst Fibros. 2003 Mar;2(1):19-24 [PMID: 15463841]
  46. Int J Antimicrob Agents. 2019 Jan;53(1):22-28 [PMID: 30268576]
  47. Expert Opin Pharmacother. 2016;17(6):761-81 [PMID: 26799840]
  48. Antimicrob Agents Chemother. 2006 Jan;50(1):368-70 [PMID: 16377714]
  49. Enferm Infecc Microbiol Clin. 2017 May;35(5):314-320 [PMID: 28017477]
  50. Intern Med J. 2018 Dec;48(12):1425-1429 [PMID: 30517987]
  51. Chemotherapy. 1977;23 Suppl 1:58-62 [PMID: 832545]
  52. J Antimicrob Chemother. 2004 May;53(5):848-52 [PMID: 15056646]
  53. Circulation. 2015 Oct 13;132(15):1435-86 [PMID: 26373316]
  54. Antimicrob Agents Chemother. 2015 Dec;59(12):7355-61 [PMID: 26369978]
  55. Rev Esp Quimioter. 2018 Feb;31(1):78-100 [PMID: 29480677]
  56. Int J Antimicrob Agents. 2014 Jan;43(1):52-9 [PMID: 24183799]
  57. Eur Heart J. 2015 Nov 21;36(44):3075-3128 [PMID: 26320109]
  58. Front Cell Infect Microbiol. 2017 Feb 15;7:39 [PMID: 28261568]
  59. Enferm Infecc Microbiol Clin. 2015 May;33(5):338-41 [PMID: 25563393]
  60. Int J Antimicrob Agents. 2016 Apr;47(4):269-85 [PMID: 27013000]
  61. J Antimicrob Chemother. 2010 May;65(5):995-8 [PMID: 20228081]
  62. Infection. 1989 May-Jun;17(3):146-51 [PMID: 2661439]
  63. Emerg Infect Dis. 2015 Nov;21(11):2045-7 [PMID: 26488485]
  64. BMJ Open. 2015 Mar 31;5(3):e007363 [PMID: 25829373]
  65. Diagn Microbiol Infect Dis. 1999 Mar;33(3):187-99 [PMID: 10092968]
  66. Antimicrob Agents Chemother. 2012 Jul;56(7):3992-5 [PMID: 22564843]
  67. Pharmacotherapy. 2014 Aug;34(8):845-57 [PMID: 24782335]
  68. Infect Drug Resist. 2013 Dec 18;7:1-7 [PMID: 24379684]

MeSH Term

Animals
Anti-Bacterial Agents
Drug Resistance, Multiple, Bacterial
Fosfomycin
Gram-Negative Bacterial Infections
Humans

Chemicals

Anti-Bacterial Agents
Fosfomycin
Journal Article Review
Article has an altmetric score of 1

Word Cloud

Created with Highcharts 10.0.0treatmentGram-negativeinfectionsresistancepathogensuseoptionFosfomycinurinarytractbacteriafosfomycinmultidrug-resistantalarmingincreaseantibioticratesreportedvariousresultedalternativepoliciesGivenfairlylimitedavailabilitynewantimicrobialdrugsreassessmentolderantibioticsnowinterestingbactericidalanalogphosphoenolpyruvatepreviouslyemployedoraluncomplicatedinfectionrecentlyraisedinterestamongphysiciansworldwidegeneraladvanceddescribedsuggestscanappropriatepatientshighlyresistantmicrobialreviewreferskeyavailabledatafocusespossibilityextendingbeyondcaused

Similar Articles

Cited By